Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kada K. Williams"'
Autor:
Daniel J. Craig, Morgan M. Bailey, Olivia B. Noe, Kada K. Williams, Laura Stanbery, Danae M. Hamouda, John J. Nemunaitis
Publikováno v:
Cancer Treatment and Research Communications, Vol 30, Iss , Pp 100507- (2022)
Tumor mutation burden (TMB) is often used as a biomarker for immunogenicity and prerequisite for immune checkpoint inhibitor (ICI) therapy. However, it is becoming increasingly evident that not all tumors with high TMB respond to ICIs as expected. It
Externí odkaz:
https://doaj.org/article/3b5f3462cb7f4ad3a40068c1b4ba12ef
Autor:
Joel A Kammeyer, Meghan M Deutsch, Victoria R Starnes, Makoto Ibaraki, Victoria Soewarna, Basmah Khalil, Katherine K Girdhar, Riaz Fabian, Justin H Franco, Stephanie L Staten, Julia T Berry, Abhishiek Setia, Kada K Williams, Rebecca A Asher, Kylie R Rostad, Caitlyn M Hollingshead
Publikováno v:
Open Forum Infectious Diseases. 9
Background Antibiotic stewardship has been a central challenge of the COVID-19 pandemic. Empiric antibiotic therapy is offered in 56.6%-74.6% of inpatients with COVID-19, with microbiologically confirmed bacterial pneumonia reported in only 3.5%-16%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d2175e2a9fc3397f45890c956ed2098
https://doi.org/10.1093/ofid/ofac492.961
https://doi.org/10.1093/ofid/ofac492.961
Autor:
Daniel J. Craig, Morgan M. Bailey, Olivia B. Noe, Kada K. Williams, Laura Stanbery, Danae M. Hamouda, John J. Nemunaitis
Publikováno v:
Cancer Treatment and Research Communications, Vol 30, Iss, Pp 100507-(2022)
Tumor mutation burden (TMB) is often used as a biomarker for immunogenicity and prerequisite for immune checkpoint inhibitor (ICI) therapy. However, it is becoming increasingly evident that not all tumors with high TMB respond to ICIs as expected. It
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f4fa53c915e87b59596efda7fef5acc
https://pubmed.ncbi.nlm.nih.gov/35007928
https://pubmed.ncbi.nlm.nih.gov/35007928
Autor:
Kaplinsky N; University of Toledo College of Medicine, Toledo, OH 43614, USA., Williams K; University of Toledo College of Medicine, Toledo, OH 43614, USA., Watkins D; University of Toledo College of Medicine, Toledo, OH 43614, USA., Adams M; University of Toledo College of Medicine, Toledo, OH 43614, USA., Stanbery L; Gradalis, Inc, Dallas, TX 75006, USA., Nemunaitis J; Gradalis, Inc, Dallas, TX 75006, USA.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (19), pp. 1367-1380. Date of Electronic Publication: 2024 Apr 23.